4D Molecular Therapeutics
Stock Forecast, Prediction & Price Target
4D Molecular Therapeutics Financial Estimates
4D Molecular Therapeutics Revenue Estimates
4D Molecular Therapeutics EBITDA Estimates
4D Molecular Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $18.03M N/A | $3.12M -82.65% | $20.72M 562.28% | Avg: $6.18M Low: $1.09M High: $8.88M avg. -70.15% | Avg: $1.99M Low: $341.69K High: $4.02M avg. -67.70% | Avg: $1.94M Low: $332.42K High: $3.91M avg. -2.71% | Avg: $17.50M Low: $2.99M High: $35.29M avg. 801.15% |
Net Income
% change YoY
| $-68.29M N/A | $-101.07M -47.99% | $-100.83M 0.23% | Avg: $-190.38M Low: $-178.04M High: $-37.17M avg. -88.80% | Avg: $-186.03M Low: $-141.65M High: $-89.99M avg. 2.28% | Avg: $-191.34M Low: $-444.03M High: $14.84M avg. -2.85% | Avg: $-245.73M Low: $-570.25M High: $19.06M avg. -28.42% |
EBITDA
% change YoY
| $-71.33M N/A | $-110.03M -54.25% | $-107.11M 2.64% | Avg: $-6.18M Low: $-8.88M High: $-1.09M avg. 94.22% | Avg: $-1.99M Low: $-4.02M High: $-341.69K avg. 67.70% | Avg: $-1.94M Low: $-3.91M High: $-332.42K avg. 2.71% | Avg: $-17.50M Low: $-35.29M High: $-2.99M avg. -801.15% |
EPS
% change YoY
| -$2.46 N/A | -$3.12 -26.82% | -$2.58 17.30% | Avg: -$2.91 Low: -$4.55 High: -$0.95 avg. -12.86% | Avg: -$3.07 Low: -$3.62 High: -$2.3 avg. -5.42% | Avg: -$4.89 Low: -$11.35 High: $0.38 avg. -59.28% | Avg: -$6.28 Low: -$14.57 High: $0.49 avg. -28.42% |
Operating Expenses
% change YoY
| $89.37M N/A | $113.16M 26.61% | $133.59M 18.05% | Avg: $20.79M Low: $3.69M High: $29.87M avg. -84.43% | Avg: $6.71M Low: $1.14M High: $13.53M avg. -67.70% | Avg: $6.53M Low: $1.11M High: $13.16M avg. -2.71% | Avg: $58.86M Low: $10.07M High: $118.65M avg. 801.15% |
FAQ
What is 4D Molecular Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -29.44% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -178.04M, average is -190.38M and high is -37.17M.
What is 4D Molecular Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 165.14% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $1.09M, average is $6.18M and high is $8.88M.
What is 4D Molecular Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -26.50% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$4.55, average is -$2.91 and high is $-0.95.
What is the best performing analyst?
In the last twelve months analysts have been covering 4D Molecular Therapeutics stock. The most successful analyst is Gena Wang.